These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18166168)

  • 41. Role of matrix metalloproteinase-9 (MMP-9) in striatal blood-brain barrier disruption in a 3-nitropropionic acid model of Huntington's disease.
    Duran-Vilaregut J; del Valle J; Manich G; Camins A; Pallàs M; Vilaplana J; Pelegrí C
    Neuropathol Appl Neurobiol; 2011 Aug; 37(5):525-37. PubMed ID: 21175737
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington's like symptoms in rats: possible role of nitric oxide.
    Kumar P; Kumar A
    Behav Brain Res; 2010 Jan; 206(1):38-46. PubMed ID: 19716383
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systemic administration of 3-nitropropionic acid points out a different role for active caspase-3 in neurons and astrocytes.
    Duran-Vilaregut J; Del Valle J; Manich G; Junyent F; Camins A; Pallàs M; Pelegrí C; Vilaplana J
    Neurochem Int; 2010 Feb; 56(3):443-50. PubMed ID: 19969037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Granulocyte colony-stimulating factor attenuates neuronal death and promotes functional recovery after spinal cord injury in mice.
    Nishio Y; Koda M; Kamada T; Someya Y; Kadota R; Mannoji C; Miyashita T; Okada S; Okawa A; Moriya H; Yamazaki M
    J Neuropathol Exp Neurol; 2007 Aug; 66(8):724-31. PubMed ID: 17882016
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease.
    Lee ST; Chu K; Park JE; Kang L; Ko SY; Jung KH; Kim M
    Brain Res; 2006 Nov; 1118(1):199-207. PubMed ID: 16959224
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanism of 3-nitropropionic acid-induced membrane permeability transition of isolated mitochondria and its suppression by L-carnitine.
    Nishimura M; Okimura Y; Fujita H; Yano H; Lee J; Suzaki E; Inoue M; Utsumi K; Sasaki J
    Cell Biochem Funct; 2008 Dec; 26(8):881-91. PubMed ID: 18942062
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolic compromise with systemic 3-nitropropionic acid produces striatal apoptosis in Sprague-Dawley rats but not in BALB/c ByJ mice.
    Alexi T; Hughes PE; Knüsel B; Tobin AJ
    Exp Neurol; 1998 Sep; 153(1):74-93. PubMed ID: 9743569
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities.
    Yang L; Calingasan NY; Chen J; Ley JJ; Becker DA; Beal MF
    Exp Neurol; 2005 Jan; 191(1):86-93. PubMed ID: 15589515
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proactive transplantation of human neural stem cells prevents degeneration of striatal neurons in a rat model of Huntington disease.
    Ryu JK; Kim J; Cho SJ; Hatori K; Nagai A; Choi HB; Lee MC; McLarnon JG; Kim SU
    Neurobiol Dis; 2004 Jun; 16(1):68-77. PubMed ID: 15207263
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transcranial magnetic stimulation attenuates cell loss and oxidative damage in the striatum induced in the 3-nitropropionic model of Huntington's disease.
    Túnez I; Drucker-Colín R; Jimena I; Medina FJ; Muñoz Mdel C; Peña J; Montilla P
    J Neurochem; 2006 May; 97(3):619-30. PubMed ID: 16524377
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease.
    Desplats PA; Kass KE; Gilmartin T; Stanwood GD; Woodward EL; Head SR; Sutcliffe JG; Thomas EA
    J Neurochem; 2006 Feb; 96(3):743-57. PubMed ID: 16405510
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity.
    DeMarch Z; Giampà C; Patassini S; Martorana A; Bernardi G; Fusco FR
    Neurobiol Dis; 2007 Feb; 25(2):266-73. PubMed ID: 17184995
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease.
    Giampà C; DeMarch Z; D'Angelo V; Morello M; Martorana A; Sancesario G; Bernardi G; Fusco FR
    Eur J Neurosci; 2006 Jan; 23(1):11-20. PubMed ID: 16420411
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model.
    Sayed NH; Fathy N; Kortam MA; Rabie MA; Mohamed AF; Kamel AS
    Neurotherapeutics; 2020 Jan; 17(1):252-268. PubMed ID: 31728850
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting oxidative/nitrergic stress ameliorates motor impairment, and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Huntington's disease.
    Pérez-De La Cruz V; Elinos-Calderón D; Robledo-Arratia Y; Medina-Campos ON; Pedraza-Chaverrí J; Ali SF; Santamaría A
    Behav Brain Res; 2009 May; 199(2):210-7. PubMed ID: 19100293
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Granulocyte colony-stimulating factor prevents reperfusion injury after heart preservation.
    Higuchi T; Yamauchi-Takihara K; Matsumiya G; Fukushima N; Ichikawa H; Kuratani T; Maehata Y; Sawa Y
    Ann Thorac Surg; 2008 Apr; 85(4):1367-73. PubMed ID: 18355530
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lack of Jun-N-terminal kinase 3 (JNK3) does not protect against neurodegeneration induced by 3-nitropropionic acid.
    Junyent F; de Lemos L; Verdaguer E; Pallàs M; Folch J; Beas-Zárate C; Camins A; Auladell C
    Neuropathol Appl Neurobiol; 2012 Jun; 38(4):311-21. PubMed ID: 21883373
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibited glutamate release by granulocyte-colony stimulating factor after experimental stroke.
    Han JL; Blank T; Schwab S; Kollmar R
    Neurosci Lett; 2008 Feb; 432(3):167-9. PubMed ID: 18255224
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration.
    Palfi S; Riche D; Brouillet E; Guyot MC; Mary V; Wahl F; Peschanski M; Stutzmann JM; Hantraye P
    Exp Neurol; 1997 Jul; 146(1):135-41. PubMed ID: 9225746
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.
    Giampà C; Middei S; Patassini S; Borreca A; Marullo F; Laurenti D; Bernardi G; Ammassari-Teule M; Fusco FR
    Eur J Neurosci; 2009 Mar; 29(5):902-10. PubMed ID: 19291221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.